Advances in Hodgkin's lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors.

HDAC inhibitors activity alone will not be sufficient for the treatment of R/R cHL, but given their disease control capacity, synergistic interaction with currently approved drugs, and ability to overcome drug resistance particularly PD-1 inhibitors, we believe that HDAC inhibitors will eventually become incorporated into the treatment armamentarium of cHL.